title: Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.
abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used drug classes. However, many patients complain of dyspeptic symptoms impairing their quality of life: ~ 20% of patients taking NSAIDs show endoscopic ulcers with or without symptoms, and up to 2% of chronic NSAID users will develop serious complications each year, such as bleeding or perforation, which are the cause of death in many patients. Coprescription of a proton pump inhibitor is one established option for the healing and prevention of NSAID-associated lesions of the upper gastrointestinal tract in patients at risk. Recent studies evaluated the clinical efficacy of esomeprazole in the management of gastrointestinal problems associated with the intake of selective and non-selective NSAIDs and aspirin.
authors.affiliation: Medical Department I, University Hospital, Dresden, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Morgner
authors.forename: Stephan
authors.initials: S
authors.lastname: Miehlke
authors.forename: Joachim
authors.initials: J
authors.lastname: Labenz
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004415:Dyspepsia / Q000188:drug therapy; D064098:Esomeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D054328:Proton Pump Inhibitors; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064098:Esomeprazole